Gordon B. Mills

Baylor College of Medicine — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

231h-index272.1kcitations3.5kworks2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(524), PI3K/AKT/mTOR signaling in cancer(315), Ovarian cancer diagnosis and treatment(239), RNA modifications and cancer(211), PARP inhibition in cancer therapy(210)

Publications3.4k total

Abstract PS2-09-24: Aurora Kinase A (AURKA) a new druggable target in ER+ Inflammatory Breast Cancer
Clinical Cancer Research·2026
Abstract PS4-01-10: Characterizing CCR7 Gene Amplification and Protein Expression in Inflammatory and non-inflammatory Breast Cancer
Clinical Cancer Research·2026
Patient-derived xenograft models of Fanconi anemia–associated head and neck cancer identify personalized therapeutic strategies
Journal of Clinical Investigation·2025Open Access
CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer
Journal of Clinical Investigation·2025· 1 citedOpen Access
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination
Nature Communications·2025Open Access
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types
Cancer Research Communications·2025Open Access
Supplemental Figure S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S3 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S5 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S1 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Table S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S4 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S6 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Table S1 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
Supplementary Data from Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
2025Open Access
page 1 of 169Next →

Frequent Co-authors

Gad Getz(21), Rehan Akbani(19), John N. Weinstein(18), Yiling Lu(18), Ina Felau(16), Michael S. Lawrence(16), Ilya Shmulevich(15), Vésteinn Thórsson(15), John A. Demchok(15), Martin L. Ferguson(15), Rupa S. Kanchi(15), Andrew D. Cherniack(14), Sudha Chudamani(14), Juok Cho(14), Nils Gehlenborg(14), David I. Heiman(14), Yuexin Liu(14), Brady Bernard(13), Carolyn M. Hutter(13), Jean C. Zenklusen(13)